tetano
Editor, Senior Moderator
Med Clin (Barc)
. 2021 Jun 18;S0025-7753(21)00367-5.
doi: 10.1016/j.medcli.2021.06.014. Online ahead of print.
Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis
[Article in English, Spanish]
Mario Fernández-Ruiz[SUP] 1 [/SUP], Francisco López-Medrano[SUP] 2 [/SUP], Octavio Carretero[SUP] 3 [/SUP], Patricia Parra[SUP] 3 [/SUP], Tamara Ruiz-Merlo[SUP] 3 [/SUP], José María Aguado[SUP] 2 [/SUP], H12O Immunomodulation Therapy for COVID-19 Group
Affiliations
Abstract
Background: The effect of immunomodulatory therapy with tocilizumab for coronavirus disease 2019 (COVID-19) in real-life clinical practice remains controversial.
Methods: Single-center retrospective matched cohort analysis including 47 consecutive patients treated with intravenous tocilizumab for severe COVID-19 pneumonia ("TCZ group"), matched by age, comorbidities, time from symptoms onset and baseline SpO[SUB]2[/SUB]/FiO[SUB]2[/SUB] ratio with 47 patients receiving standard of care alone ("SoC group").
Results: There were no significant differences between the TCZ and SoC groups in the rate of clinical improvement (hospital discharge and/or a decrease of ≥2 points on a six-point ordinal scale) by day 7 (51.1% [24/47] versus 48.9% [23/47]; P-value=1.000). No differences were observed at day 14 in terms of clinical improvement (72.3% versus 76.6%; P-value=0.791), all-cause mortality (10.6% versus 12.8%; P-value=1.000), and the composite of invasive mechanical ventilation and/or death (25.5% versus 23.4%; P-value=1.000) either. Patients in the TCZ group had a more rapid normalization of C-reactive protein levels.
Conclusions: No apparent benefit was observed in patients with severe COVID-19 treated with tocilizumab as compared to a matched retrospective cohort.
Keywords: COVID-19; Estudio de cohortes pareadas; Evolución; Immunomodulatory therapy; Matched cohort study; Outcome; Tocilizumab; Tratamiento inmunomodulador.
. 2021 Jun 18;S0025-7753(21)00367-5.
doi: 10.1016/j.medcli.2021.06.014. Online ahead of print.
Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis
[Article in English, Spanish]
Mario Fernández-Ruiz[SUP] 1 [/SUP], Francisco López-Medrano[SUP] 2 [/SUP], Octavio Carretero[SUP] 3 [/SUP], Patricia Parra[SUP] 3 [/SUP], Tamara Ruiz-Merlo[SUP] 3 [/SUP], José María Aguado[SUP] 2 [/SUP], H12O Immunomodulation Therapy for COVID-19 Group
Affiliations
- PMID: 34243954
- DOI: 10.1016/j.medcli.2021.06.014
Abstract
Background: The effect of immunomodulatory therapy with tocilizumab for coronavirus disease 2019 (COVID-19) in real-life clinical practice remains controversial.
Methods: Single-center retrospective matched cohort analysis including 47 consecutive patients treated with intravenous tocilizumab for severe COVID-19 pneumonia ("TCZ group"), matched by age, comorbidities, time from symptoms onset and baseline SpO[SUB]2[/SUB]/FiO[SUB]2[/SUB] ratio with 47 patients receiving standard of care alone ("SoC group").
Results: There were no significant differences between the TCZ and SoC groups in the rate of clinical improvement (hospital discharge and/or a decrease of ≥2 points on a six-point ordinal scale) by day 7 (51.1% [24/47] versus 48.9% [23/47]; P-value=1.000). No differences were observed at day 14 in terms of clinical improvement (72.3% versus 76.6%; P-value=0.791), all-cause mortality (10.6% versus 12.8%; P-value=1.000), and the composite of invasive mechanical ventilation and/or death (25.5% versus 23.4%; P-value=1.000) either. Patients in the TCZ group had a more rapid normalization of C-reactive protein levels.
Conclusions: No apparent benefit was observed in patients with severe COVID-19 treated with tocilizumab as compared to a matched retrospective cohort.
Keywords: COVID-19; Estudio de cohortes pareadas; Evolución; Immunomodulatory therapy; Matched cohort study; Outcome; Tocilizumab; Tratamiento inmunomodulador.